Abstract 432P
Background
Basal cell carcinoma (BCC) is the most common cancer. Surgical excision is the primary treatment of BCC. Radiotherapy and topical therapies are other treatment options. Vismodegib inhibits the hedgehog signaling pathway that is an important mechanism of developing BCC. The study aims to evaluate the vismodegib treatment in local advanced (laBCC) and metastatic (mBCC) basal cell carcinoma.
Methods
The data of 29 patients were retrospectively reviewed. The clinical and histopathological features of the patients and adverse events of vismodegib treatment were recorded. Overall survival (OS) and progression-free survival (PFS) evaluated with Kaplan-Meier analysis.
Results
The median follow-up period was 17 months (range: 1.6-57.3). The median age at diagnosis was 73 years (range: 39-88). The percentages of female and male patients were 51.7% and 48.3%, respectively. The most common location of disease was head and neck (86.2%). The number of metastatic patients was 5 (17.2%). The most common non-skin locations of disease were lymph nodes-13.8%, bone-13.8%, lung-6.9%, and brain-6.9%. Three (10.3%) patients had Gorlin’s syndrome. Before vismodegib treatment, 15 (51.7%) patients had received radiotherapy and 18 (62.1%) patients had undergone surgery. With vismodegib treatment, the complete response rate was 27.6% and partial response 55.2%, and stable response 10.3%. Treatment responses were most frequently seen within two months from the beginning of vismodegib. The most common adverse events were fatigue-58.6%, muscle spasms-48.3%, alopecia-13.8%, and weight loss- 13.8%. A total of 8 (27.6%) patients deceased during the study period. The median OS was 43.3±9.0 months (25.6-61.1) for all patients. The median PFS in the laBCC was 15.7±1.8 months (12.2-19.3). The median PFS in the mBCC was 12.1±4.6 months (2.9-21.2). After the disease progression under vismodegib treatment, 53.8% of the patients received chemotherapy or had surgical treatment.
Conclusions
In this study, we determined that vismodegib treatment in locally advanced and metastatic BCC was well tolerated and effective.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Real world outcomes in elderly women with HER2-positive advanced breast cancer
Presenter: Nicole Evans
Session: e-Poster Display Session
52P - Chemotherapy selection in routine clinical practice in Japan for HER2-negative advanced or metastatic breast cancer (KBCRN A001: E-SPEC Study)
Presenter: Yookija Kang
Session: e-Poster Display Session
53P - Aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor treated HR+/HER2- metastatic breast cancer differ to those treated with Aromatase inhibitors alone on progression
Presenter: Indunil Weerasena
Session: e-Poster Display Session
54P - Platinum-based chemotherapy in advanced breast cancer (ABC): Real-world outcome from a tertiary cancer centre in India
Presenter: Indhuja Vijesh
Session: e-Poster Display Session
55P - Eribulin in heavily pretreated metastatic breast cancer: A real-world data from India
Presenter: Tanmoy Mandal
Session: e-Poster Display Session
56P - Treatment of palbociclib in hormone receptor-positive breast cancer in China: A real-world study
Presenter: Yiqi Yang
Session: e-Poster Display Session
57P - Therapeutic vulnerability of malignant phyllodes tumour to pazopanib identified through a novel patient-derived xenograft and cell line model
Presenter: Dave Ng
Session: e-Poster Display Session
58P - Survival benefit of local treatments in breast cancer with lung metastasis: Results from a large retrospective study
Presenter: Yimeng Chen
Session: e-Poster Display Session
59P - The impact of site of metastasis on overall survival in indigenous and non-indigenous patients of Western Australia with breast cancer
Presenter: Azim Khan
Session: e-Poster Display Session
60P - Risk factors of bone metastasis and skeletal-related events in high-risk breast cancer patients
Presenter: Sumadi Lukman Anwar
Session: e-Poster Display Session